This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from being converted into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time.

It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

It is an antihistamine that can relieve symptoms such as runny nose, nasal congestion, and sneezing.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.